Original Publication Date: 1 September, 2015
Publication / Source: Personalized Medicine
Authors: Raphaël Maréchal, Francesco Puleo, Anne Demols, Gontran Verset & Jean-Luc Van Laethem
Pancreatic ductal adenocarcinoma carries a dismal prognosis. Both chemotherapy and targeted therapies have been disappointing when administered to unselected populations. Recently, progress has been made in our understanding of the genomic landscape of this cancer which displays remarkable heterogeneity suggesting a reorientation of management and research strategies based on molecular characterization and adapted personalized therapy.